G enetic testing company Myriad Genetics, the defendant in a landmark Supreme Court case over gene patents, is back in the spotlight — this time, for withholding genetic data from patients ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS ...

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...

Myriad Genetics disparages its competitors for alleged mistakes in interpreting BRCA gene tests, but STAT found the company's claims were overstated.

Genetic tests like one offered by Myriad Genetics claim to analyze a patient's DNA and point them to the best depression drug for them. Myriad's test is called GeneSight and costs $2,000.

Image source: Myriad Genetics. April showers bring myriad flowers. That's not really how the old adage goes, but the changed wording just might be.

Myriad Genetics pioneered and was the market leader in BRCA testing for over ten years. Analysts write that CEO Paul Diaz has successfully addressed Myriad's operational and innovation challenges ...

Genetic testing firm Myriad Genetics has tapped scientist and veteran biopharma lawyer Jennifer Fox to be its legal chief starting in September, the company announced Wednesday. Fox comes from ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved ...